SG11202101547WA - Pharmaceutical composition for oral administration - Google Patents

Pharmaceutical composition for oral administration

Info

Publication number
SG11202101547WA
SG11202101547WA SG11202101547WA SG11202101547WA SG11202101547WA SG 11202101547W A SG11202101547W A SG 11202101547WA SG 11202101547W A SG11202101547W A SG 11202101547WA SG 11202101547W A SG11202101547W A SG 11202101547WA SG 11202101547W A SG11202101547W A SG 11202101547WA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
oral administration
oral
administration
pharmaceutical
Prior art date
Application number
SG11202101547WA
Inventor
Ryo Kojima
Toshiro Sakai
Ryota Azuma
Marina Tanaka
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of SG11202101547WA publication Critical patent/SG11202101547WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG11202101547WA 2018-08-31 2019-08-30 Pharmaceutical composition for oral administration SG11202101547WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018163234 2018-08-31
PCT/JP2019/034051 WO2020045607A1 (en) 2018-08-31 2019-08-30 Pharmaceutical composition for oral administration

Publications (1)

Publication Number Publication Date
SG11202101547WA true SG11202101547WA (en) 2021-03-30

Family

ID=69642788

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101547WA SG11202101547WA (en) 2018-08-31 2019-08-30 Pharmaceutical composition for oral administration

Country Status (14)

Country Link
US (1) US20210346392A1 (en)
EP (1) EP3845230B1 (en)
JP (1) JP7355020B2 (en)
KR (1) KR20210052495A (en)
CN (1) CN112638390A (en)
CA (1) CA3108993C (en)
ES (1) ES2958158T3 (en)
MX (1) MX2021002385A (en)
PH (1) PH12021550251A1 (en)
PL (1) PL3845230T3 (en)
PT (1) PT3845230T (en)
SG (1) SG11202101547WA (en)
TW (1) TW202023565A (en)
WO (1) WO2020045607A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022123701A1 (en) 2020-12-09 2022-06-16 昭和電工マテリアルズ株式会社 Packed negative electrode material, negative electrode material transportation method, negative electrode material storage container, and negative electrode material storage method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58134033A (en) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd Drug composition
KR101422301B1 (en) * 2006-04-26 2014-07-30 에프. 호프만-라 로슈 아게 Pharmaceutical compounds
BR112016007588A2 (en) * 2013-10-17 2017-09-12 Bayer Pharma AG pharmaceutical dosage forms comprising 1- [6- (morpholin-4-yl) pyrimidin-4-yl] -4- (1h-1,2,3-triazol-1-yl) -1h-pyrazol-5-olate sodium
TWI648281B (en) * 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 Sulfur-containing bicyclic compound

Also Published As

Publication number Publication date
CA3108993A1 (en) 2020-03-05
CN112638390A (en) 2021-04-09
PL3845230T3 (en) 2023-12-27
JPWO2020045607A1 (en) 2021-08-12
EP3845230B1 (en) 2023-07-12
JP7355020B2 (en) 2023-10-03
WO2020045607A1 (en) 2020-03-05
EP3845230A1 (en) 2021-07-07
CA3108993C (en) 2023-10-17
MX2021002385A (en) 2021-04-29
EP3845230A4 (en) 2022-06-01
PT3845230T (en) 2023-09-27
TW202023565A (en) 2020-07-01
ES2958158T3 (en) 2024-02-02
US20210346392A1 (en) 2021-11-11
KR20210052495A (en) 2021-05-10
PH12021550251A1 (en) 2021-10-11

Similar Documents

Publication Publication Date Title
IL258464A (en) Pharmaceutical formulations for the oral delivery of peptide drugs
IL270812A (en) Solid compositions for oral administration
HUP1700253A1 (en) Solid preparations for oral administration
HK1248544A1 (en) Stable pharmaceutical composition for oral administration
EP3784214A4 (en) Liquid oral pharmaceutical dosage form
IL282163A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
IL290469A (en) Oral pharmaceutical composition
HK1245646A1 (en) Pharmaceutical composition for oral administration
GB2591396B (en) Pharmaceutical suspension for oral dosage
SG11202101547WA (en) Pharmaceutical composition for oral administration
IL282842A (en) Pharmaceutical formulations for subcutaneous administration
EP3880171C0 (en) Ibuprofen-containing oral pharmaceutical formulation
FI3908321T3 (en) Pharmaceutical composition
PT3650024T (en) Pharmaceutical composition for nasal administration
HK1232144A1 (en) Pharmaceutical composition for oral administration
GB2561723B (en) A composition for oral administration
GB201908003D0 (en) Pharmaceutical composition